Oral Formulation Based on Irbesartan Nanocrystals Improve Drug Solubility, Absorbability, and Efficacy
We previously reported that the bioavailability (BA) of irbesartan (IRB), a BSC class II drug, was improved by preparing nanocrystalline suspensions. However, nanocrystalline suspensions have chemical and physical instabilities and must be converted into tablets through drying approaches in order to...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875686/ https://www.ncbi.nlm.nih.gov/pubmed/35214118 http://dx.doi.org/10.3390/pharmaceutics14020387 |
_version_ | 1784657992740765696 |
---|---|
author | Nagai, Noriaki Ogata, Fumihiko Ike, Ayari Shimomae, Yurisa Osako, Hanano Nakazawa, Yosuke Yamamoto, Naoki Kawasaki, Naohito |
author_facet | Nagai, Noriaki Ogata, Fumihiko Ike, Ayari Shimomae, Yurisa Osako, Hanano Nakazawa, Yosuke Yamamoto, Naoki Kawasaki, Naohito |
author_sort | Nagai, Noriaki |
collection | PubMed |
description | We previously reported that the bioavailability (BA) of irbesartan (IRB), a BSC class II drug, was improved by preparing nanocrystalline suspensions. However, nanocrystalline suspensions have chemical and physical instabilities and must be converted into tablets through drying approaches in order to overcome such instabilities. In this study, we attempted to design a molded tablet based on nanocrystalline IRB suspensions (IRB-NP tablet) and investigated the effects of this IRB-NP tablet on blood pressure (BP) in a stroke-prone spontaneously hypertensive (SHR-SP) rat. The IRB-NP tablet (with a hardness of 42.6 N) was developed by combining various additives (methylcellulose, 2-hydroxypropyl-β-cyclodextrin HPβCD, D-mannitol, polyvinylpyrrolidone, and gum arabic) followed by bead-milling and freeze-drying treatments. The mean particle size in the redispersions of the IRB-NP tablet was approximately 118 nm. The solubility and intestinal absorption of IRB in the IRB-NP tablet were significantly enhanced in comparison with the microcrystalline IRB tablet (IRB-MP tablet), and both solubility and clathrin-dependent endocytosis helped improve the low BA of the IRB. In addition, the BP-reducing effect of the IRB-NP tablet was significantly higher than that of the IRB-MP tablet. These results provide useful information for the preservation of nanocrystalline suspensions of BCS class II drugs, such as IRB. |
format | Online Article Text |
id | pubmed-8875686 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-88756862022-02-26 Oral Formulation Based on Irbesartan Nanocrystals Improve Drug Solubility, Absorbability, and Efficacy Nagai, Noriaki Ogata, Fumihiko Ike, Ayari Shimomae, Yurisa Osako, Hanano Nakazawa, Yosuke Yamamoto, Naoki Kawasaki, Naohito Pharmaceutics Article We previously reported that the bioavailability (BA) of irbesartan (IRB), a BSC class II drug, was improved by preparing nanocrystalline suspensions. However, nanocrystalline suspensions have chemical and physical instabilities and must be converted into tablets through drying approaches in order to overcome such instabilities. In this study, we attempted to design a molded tablet based on nanocrystalline IRB suspensions (IRB-NP tablet) and investigated the effects of this IRB-NP tablet on blood pressure (BP) in a stroke-prone spontaneously hypertensive (SHR-SP) rat. The IRB-NP tablet (with a hardness of 42.6 N) was developed by combining various additives (methylcellulose, 2-hydroxypropyl-β-cyclodextrin HPβCD, D-mannitol, polyvinylpyrrolidone, and gum arabic) followed by bead-milling and freeze-drying treatments. The mean particle size in the redispersions of the IRB-NP tablet was approximately 118 nm. The solubility and intestinal absorption of IRB in the IRB-NP tablet were significantly enhanced in comparison with the microcrystalline IRB tablet (IRB-MP tablet), and both solubility and clathrin-dependent endocytosis helped improve the low BA of the IRB. In addition, the BP-reducing effect of the IRB-NP tablet was significantly higher than that of the IRB-MP tablet. These results provide useful information for the preservation of nanocrystalline suspensions of BCS class II drugs, such as IRB. MDPI 2022-02-10 /pmc/articles/PMC8875686/ /pubmed/35214118 http://dx.doi.org/10.3390/pharmaceutics14020387 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Nagai, Noriaki Ogata, Fumihiko Ike, Ayari Shimomae, Yurisa Osako, Hanano Nakazawa, Yosuke Yamamoto, Naoki Kawasaki, Naohito Oral Formulation Based on Irbesartan Nanocrystals Improve Drug Solubility, Absorbability, and Efficacy |
title | Oral Formulation Based on Irbesartan Nanocrystals Improve Drug Solubility, Absorbability, and Efficacy |
title_full | Oral Formulation Based on Irbesartan Nanocrystals Improve Drug Solubility, Absorbability, and Efficacy |
title_fullStr | Oral Formulation Based on Irbesartan Nanocrystals Improve Drug Solubility, Absorbability, and Efficacy |
title_full_unstemmed | Oral Formulation Based on Irbesartan Nanocrystals Improve Drug Solubility, Absorbability, and Efficacy |
title_short | Oral Formulation Based on Irbesartan Nanocrystals Improve Drug Solubility, Absorbability, and Efficacy |
title_sort | oral formulation based on irbesartan nanocrystals improve drug solubility, absorbability, and efficacy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875686/ https://www.ncbi.nlm.nih.gov/pubmed/35214118 http://dx.doi.org/10.3390/pharmaceutics14020387 |
work_keys_str_mv | AT nagainoriaki oralformulationbasedonirbesartannanocrystalsimprovedrugsolubilityabsorbabilityandefficacy AT ogatafumihiko oralformulationbasedonirbesartannanocrystalsimprovedrugsolubilityabsorbabilityandefficacy AT ikeayari oralformulationbasedonirbesartannanocrystalsimprovedrugsolubilityabsorbabilityandefficacy AT shimomaeyurisa oralformulationbasedonirbesartannanocrystalsimprovedrugsolubilityabsorbabilityandefficacy AT osakohanano oralformulationbasedonirbesartannanocrystalsimprovedrugsolubilityabsorbabilityandefficacy AT nakazawayosuke oralformulationbasedonirbesartannanocrystalsimprovedrugsolubilityabsorbabilityandefficacy AT yamamotonaoki oralformulationbasedonirbesartannanocrystalsimprovedrugsolubilityabsorbabilityandefficacy AT kawasakinaohito oralformulationbasedonirbesartannanocrystalsimprovedrugsolubilityabsorbabilityandefficacy |